View printer-friendly version
<< Back
CytomX Therapeutics to Present Data from Anti-Jagged Probody Program at Upcoming AACR Annual Meeting 2014

Program includes Probody™ and PDC Product Candidates Targeting Notch Pathway

SOUTH SAN FRANCISCO, Calif., March 26, 2014 – CytomX Therapeutics, the Probody™ therapeutics company, today announced that preclinical and translational data from its novel Jagged program will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-9, 2014 at the San Diego Convention Center in San Diego, Calif.

CytomX is advancing two novel, first-in-class product candidates targeting Jagged ligands in the Notch pathway. CTX-033 is an anti-Jagged Probody that blocks Jagged-dependent Notch signaling. CTX-1003 is an anti-Jagged Probody Drug Conjugate (PDC) that utilizes Jagged ligands as tumor antigens to deliver a cytotoxic payload to tumor cells. The Notch pathway has been identified as an important developmental signaling pathway involved in multiple aspects of tumor biology in a number of solid and hematologic tumors. However, Notch receptors and ligands are also widely expressed in healthy tissue. CTX-033, a Probody targeting Jagged ligands 1 and 2, is activated locally in the tumor microenvironment and induces dose-dependent inhibition of Notch signaling, resulting in anti-tumor activity in in vivo tumor models without incurring the toxicities typically associated with systemic blockade of Notch signaling. Preclinical data on CTX-1003, a PDC targeting Jagged 1 and 2, shows potent anti-tumor activity and support a Probody drug conjugate approach to this highly expressed target in a number of cancer types.

“These data demonstrate the ability of our Probody platform to produce first in class, highly differentiated therapies for the treatment of cancer,” said Sean McCarthy, D.Phil., chief executive officer of CytomX. “We have made rapid progress in the advancement of our proprietary pipeline and we look forward to further advancing the Jagged program toward clinical testing.”

The schedule for the CytomX poster presentations is as follows:
Date & Time: Monday, April 7, 2014 from 1:00-5:00 p.m. (PT)
Abstract Number: 2664
Presentation Title: An anti-Jagged- 1/-2 Probody demonstrates inhibition of Jagged-dependent
Notch signaling and is activated in multiple types of tumors
Location: Hall A-E, Poster Section 31
Poster Board Number: 25
Date & Time: Monday, April 7, 2014 from 1:00-5:00 p.m. (PT)
Abstract Number: 2665
Presentation Title: Transforming Notch ligands into tumor-antigen targets: A Probody-Drug
Conjugate (PDC) targeting Jagged 1 and Jagged 2
Location: Hall A-E, Poster Section 31
Poster Board Number: 26